- Home
- KMI vs EW Comparison
KMI vs EW Comparison
Compare KMI & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KMI | EW |
|---|---|---|
| Founded | 1936 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Industrial Specialties |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.5B | 49.5B |
| IPO Year | 2011 | 2000 |
Fundamental Metrics
Financial Performance| Metric | KMI | EW |
|---|---|---|
| Price | $27.19 | $85.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 20 |
| Target Price | $31.43 | ★ $96.11 |
| AVG Volume (30 Days) | ★ 11.3M | 3.0M |
| Earning Date | 01-21-2026 | 02-10-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | ★ 7.28 | N/A |
| EPS | 1.22 | ★ 2.33 |
| Revenue | ★ $16,416,000,000.00 | $5,883,800,000.00 |
| Revenue This Year | $12.26 | $14.29 |
| Revenue Next Year | $4.78 | $9.68 |
| P/E Ratio | ★ $22.35 | $36.30 |
| Revenue Growth | 8.35 | ★ 10.60 |
| 52 Week Low | $23.94 | $65.94 |
| 52 Week High | $31.48 | $87.89 |
Technical Indicators
Market Signals| Indicator | KMI | EW |
|---|---|---|
| Relative Strength Index (RSI) | 50.39 | 51.58 |
| Support Level | $26.59 | $83.93 |
| Resistance Level | $28.00 | $86.60 |
| Average True Range (ATR) | 0.49 | 1.38 |
| MACD | -0.01 | -0.19 |
| Stochastic Oscillator | 49.70 | 44.58 |
Price Performance
Historical ComparisonAbout KMI Kinder Morgan Inc.
Kinder Morgan operates natural gas, crude oil, and refined products pipelines connecting producing regions to demand centers. It is principally involved in the gathering, storage, and transmission of natural gas across the continental United States. It also operates distribution centers for refined products along with the largest fleet of Jones Act-compliant tankers.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.